Minghuan Li

List of Publications by Year
in descending order

		623734	677142
40 papers	556 citations	14 h-index	22 g-index
40 all docs	40 docs citations	40 times ranked	1069 citing authors

#	Article	IF	Citations
1	Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis. Frontiers in Oncology, 2021, 11, 600844.	2.8	6
2	Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. BMC Cancer, 2021, 21, 66.	2.6	10
3	Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients. Radiation Oncology, 2021, 16, 195.	2.7	1
4	The PET-Derived Tumor-to-Liver Standard Uptake Ratio (SUVTLR) Is Superior to Tumor SUVmax in Predicting Tumor Response and Survival After Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer. Frontiers in Oncology, 2020, 10, 1630.	2.8	15
5	Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma. Translational Cancer Research, 2020, 9, 3842-3853.	1.0	11
6	A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092682.	3.2	28
7	A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR. BMC Cancer, 2020, 20, 544.	2.6	17
8	The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. EJNMMI Research, 2020, 10, 57.	2.5	2
9	The impact of the nodal status on the overall survival of non-surgical patients with esophageal squamous cell carcinoma. Radiation Oncology, 2019, 14, 161.	2.7	5
10	<p>Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma</p>. Cancer Management and Research, 2019, Volume 11, 2269-2280.	1.9	12
11	<p>Baseline FDG Uptake And Peripheral Lymphocyte-Monocyte Ratio For Predicting Chemoradiotherapy Response In Patients With Esophageal Squamous Cell Carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 9085-9093.	1.9	2
12	Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Future Oncology, 2019, 15, 625-635.	2.4	16
13	High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma. Oncology Letters, 2019, 18, 4691-4702.	1.8	5
14	Radiotherapy for esophageal carcinoma: dose, response and survival. Cancer Management and Research, 2018, Volume 10, 13-21.	1.9	23
15	Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thoracic Cancer, 2018, 9, 726-735.	1.9	28
16	Prognostic role of neutrophilâ€toâ€lymphocyte ratio on esophageal cancer patients who received definitive chemoradiotherapy. Precision Radiation Oncology, 2018, 2, 32-38.	1.1	0
17	Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation. Cancer Management and Research, 2018, Volume 10, 3199-3205.	1.9	9
18	Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study. Thoracic Cancer, 2018, 9, 865-873.	1.9	8

#	Article	IF	Citations
19	Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 2643-2650.	2.4	30
20	<sup>18</sup>F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. OncoTargets and Therapy, 2018, Volume 11, 4345-4353.	2.0	4
21	Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response. OncoTargets and Therapy, 2018, Volume 11, 2509-2517.	2.0	11
22	Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead. Cancer Letters, 2017, 401, 46-52.	7.2	1
23	Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2017, 66, 343-354.	4.2	42
24	The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. Oncotarget, 2017, 8, 33736-33744.	1.8	19
25	Consolidative thoracic radiotherapy for extensive stage small cell lung cancer. Oncotarget, 2017, 8, 22251-22261.	1.8	11
26	Identification of risk factors and the pattern of lower cervical lymph node metastasis in esophageal cancer: implications for radiotherapy target delineation. Oncotarget, 2017, 8, 43389-43396.	1.8	4
27	Inhibition of hypoxia-inducible factor-1α by PX-478 as a potential targeted therapy in ESCC.. Journal of Clinical Oncology, 2017, 35, e14083-e14083.	1.6	0
28	Prognostic significance of the lymphocyte‐to‐monocyte ratio and the tumor‐infiltrating lymphocyte to tumor‐associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2017, 35, e15602-e15602.	1.6	0
29	Association of CD8+/FOXP3+ ratio and PD-L1 expression with survival in pT3N0M0 stage esophageal squamous cell cancer.. Journal of Clinical Oncology, 2017, 35, e15517-e15517.	1.6	0
30	Details of out-field regional recurrence after involved-field irradiation with concurrent chemotherapy for locally advanced esophageal squamous cell carcinoma. OncoTargets and Therapy, 2016, 9, 3049.	2.0	5
31	Mapping patterns of nodal metastases in esophageal carcinoma: rethinking the clinical target volume for supraclavicular nodal irradiation. Journal of Thoracic Disease, 2016, 8, 3132-3138.	1.4	3
32	Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget, 2016, 7, 52436-52441.	1.8	13
33	Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation. OncoTargets and Therapy, 2016, Volume 9, 4187-4196.	2.0	14
34	Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma—a review. Tumor Biology, 2016, 37, 14443-14450.	1.8	1
35	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 753-761.	3.6	73
36	How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy. Cancer Biology and Therapy, 2016, 17, 125-128.	3.4	9

#	ARTICLE	IF	CITATIONS
37	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget, 2016, 7, 71455-71465.	1.8	42
38	FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients WithÂBone Metastasis From Nonâ€"small-cell LungÂCancer. Clinical Lung Cancer, 2015, 16, e111-e119.	2.6	14
39	Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiation Oncology, 2014, 9, 64.	2.7	38
40	Prognostic value of 3â€²-Deoxy-3â€²-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas. Nuclear Medicine and Biology, 2014, 41, 710-715.	0.6	24